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license (http://creativebrospinal fluid (CSF) has previously been shown to be increased in Alzheimer’s disease (AD) and
thus may serve as an outcome measure in clinical trials and facilitate earlier disease detection.
Methods: We developed an enzyme-linked immunosorbent assay for CSF GAP-43 and measured
healthy controls (n5 43), patients with AD (n5 275), or patients with other neurodegenerative dis-
eases (n5 344). In a subpopulation (n5 93), CSF GAP-43 concentrations from neuropathologically
confirmed cases were related to Ab plaques, tau, a-synuclein, and TDP-43 pathologies.
Results: GAP-43 was significantly increased in AD compared to controls and most neurodegenera-
tive diseases and correlated with the magnitude of neurofibrillary tangles and Ab plaques in the hip-
pocampus, amygdala, and cortex. GAP-43 was not associated to a-synuclein or TDP-43 pathology.
Discussion: The presynaptic marker GAP-43 is associated with both diagnosis and neuropathology
of AD and thus may be useful as a sensitive and specific biomarker for clinical research.
 2018 The Authors. Published by Elsevier Inc. on behalf of the Alzheimer’s Association. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).Keywords: GAP-43; CSF biomarker; Alzheimer’s disease; Differential diagnosis; Enzyme-linked immunosorbent assaythor. Tel.: 146 31 343 24 19; Fax: 146 31-419289.
a.sandelius@neuro.gu.se
/j.jalz.2018.08.006
e Authors. Published by Elsevier Inc. on behalf of the Alzhe
commons.org/licenses/by-nc-nd/4.0/).
FLA 5.5.0 DTD  JALZ2745_proof 1. Background
Alzheimer’s disease (AD) patients constitute a heteroge-
neous group, and patients with other neurodegenerative
diseases such as frontotemporal lobar degeneration (FTD),
dementia with Lewy bodies (DLB), and Parkinson’s diseaseimer’s Association. This is an open access article under the CC BY-NC-ND
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which complicates the diagnosis [1,2]. In addition to clinical
evaluation, three core cerebrospinal fluid (CSF) biomarkers
are currently used for diagnosis of AD; the 42 amino
acid form of amyloid b (Ab42), total-tau (T-tau), and phos-
phorylated tau (P-tau), reflecting amyloid pathology, neuro-
degeneration, and tangle pathology, respectively, are
included in the diagnostic criteria for AD [3,4]. Recently,
disease-modifying drugs targeting Ab pathology, such as
b-secretase inhibitors and the anti-Ab antibody aducanu-
mab, have shown promising results [5,6] highlighting an
increasing need to correctly identify patients with AD
pathology. Furthermore, such therapeutics is expected to
be most effective at the early stages of AD before neuronal
damage is too widespread.
It is known that pathological changes due to AD occur
long before clinical symptoms appear. Therefore, it is impor-
tant to diagnose patients as early as possible. It is widely
recognized that synaptic dysfunction is an early core feature
of AD and synaptic dysfunction and loss is highly correlated
to cognitive decline [7–10]. Thus, additional biomarkers
reflecting synaptic dysfunction and loss may further
improve differential diagnosis, be useful as outcome
markers in clinical trials, provide novel disease stage
information, and enable earlier diagnosis in combination
with the core biomarkers.
Growth-associated protein 43 (GAP-43) is a presynaptic
protein highly expressed during neuronal development and
synaptogenesis and thereafter in the hippocampus and asso-
ciation cortices in the adult human brain [11–13].
Furthermore, GAP-43 is involved in the regulation of axonal
outgrowth, synaptic plasticity, and learning and memory
functions [14–19], and previous postmortem brain studies
of GAP-43 reported decreased protein expression in frontal
cortex and regional increases in the hippocampus of patients
with AD [20–22]. In a recent explorative study including
280 proteins, it was shown that the fluorescence intensity
per bead identity and sample for CSF GAP-43 was increased
in preclinical and clinical AD compared to controls, while
there were no significant changes in PD or DLB patients
compared to controls [23]. However, assay characterization
was not provided. Previous CSF quantification of GAP-43 in
the early 2000s showed a decrease in PD but normal or only
slightly increased concentration in AD compared to neuro-
logical controls [24,25]. Discrepancies between the studies
may be due to assay differences or the lack of knowledge
at the time regarding differential diagnosis leading to
mixed patient cohorts. Current knowledge on differential
diagnosis allows for more homogeneous patient cohorts,
which increases the chances of finding actual AD-specific
biomarkers. Therefore, we developed and validated a novel
enzyme-linked immunosorbent assay (ELISA) for quantifi-
cation of GAP-43 in CSF and analyzed a large, well-
characterized cohort including controls and clinically
diagnosed AD patients and other dementia patients. A sub-
population of patients was neuropathologically assessed forFLA 5.5.0 DTD  JALZ2745_proof amyloid, tau, a-synuclein, TDP pathology, and neuron loss
in several different brain regions allowing for the first time
an evaluation of associations between CSF GAP-43 concen-
tration and several dementia pathologies. Furthermore,
GAP-43 CSF concentration was tested for association
with global cognition and decline over a 2-year period using
the Mini–Mental State Examination (MMSE) score. The
following hypotheses were tested: (1) CSF GAP-43 is espe-
cially affected in AD and useful for differential diagnosis;
(2) CSF GAP-43 quantification is associated to cognitive




The pilot study included 15 AD patients and 12 controls.
Demographics are summarized in Supplementary Table 1.
Ab42, T-tau, and P-tau were used for neurochemical classifi-
cation of the patients into AD or control groups.
2.1.2. Clinical validation study
The clinical validation study included 662 participants
from the University of Pennsylvania Integrated NeuroDe-
generative Disease Database [26], comprising participants
without signs of neurodegenerative diseases serving as con-
trols (n 5 43), mild cognitive impairment (MCI) (n 5 84),
AD (n 5 275), amyotrophic lateral sclerosis (ALS)
(n 5 53, of which ALS with MCI n 5 3, ALS with FTD
n5 9), behavioral variant FTD (bvFTD, n5 39), noncogni-
tively impaired PD (n5 28), PDwithMCI (n5 14), PDwith
dementia (n 5 15), DLB (n 5 27), logopenic variant of pri-
mary progressive aphasia (lvPPA, n5 10), semantic demen-
tia variant of primary progressive aphasia (svPPA, n 5 16),
progressive nonfluent aphasia variant of primary progressive
aphasia (naPPA, n 5 15), progressive supranuclear palsy
(n 5 18), corticobasal syndrome (n 5 19), and posterior
cortical atrophy (PCA, n 5 6) patients. CSF sampling was
performed according to standard operating procedures of
the Alzheimer’s Disease Neuroimaging Initiative (http://
www.adni-info.org/).
MMSE score was available for 593 subjects. Two-year
follow-up MMSE scores were available for 305 subjects,
and the decline in MMSE score per year was used to analyze
the association between GAP-43 and cognitive decline.
In 93 patients, Braak neurofibrillary tau staging and Con-
sortium to Establish a Registry for Alzheimer’s Disease (CE-
RAD) score was performed as previously described [26].
Furthermore, postmortem examination and scoring of tau,
thioflavin/amyloid, a-synuclein, and TDP-43 pathology, as
well as amyloid angiopathy, gliosis, and neuron loss, was
carried out on brain sections from 17 brain regions: amyg-
dala, cornu ammonis/subiculum-hippocampus, entorhinal
cortex-hippocampus, midfrontal cortex, angular gyrus,2 November 2018  10:29 pm  ce
A. Sandelius et al. / Alzheimer’s & Dementia- (2018) 1-10 3superior-midtemporal cortex, anterior cingulate cortex, oc-
cipital (visual, calcarine) cortex, caudate/putamen, globus
pallidus, thalamus, midbrain, substantia nigra–midbrain,
pons, locus coeruleus-pons, medulla, and dentate nucleus-
cerebellum. Sections were processed and histologically
(thioflavin S) or immunohistochemically stained (phosphor-
ylated tau, a-synuclein, TDP-43) and graded using a five-
point scale (0 5 none, 0.5 5 rare, 1 5 mild, 2 5 moderate,
3 5 severe) as previously described [26,27]. GAP-43 con-
centrations across this scale were compared for the
mentioned stains across the 17 brain regions, after merging
data from points 0 and 0.5 due to low numbers. Genomic
DNAwas extracted as described elsewhere [26], for determi-
nation of APOE allele status using two SNPs (rs7412 and
rs429358), genotyped by TaqMan allelic discrimination as-
says (Thermo-Fisher, USA).
2.2. Ethics
The pilot study on leftover aliquots from clinical routine
analyses followed a procedure approved by the Ethics Com-
mittee at University of Gothenburg (EPN140811). The clin-
ical validation study was conducted in accordance with the
provisions of the Helsinki declaration and approved by
regional ethics committee.
2.3. AD biomarker quantification
In the clinical validation study, quantification of CSF
T-tau, P-tau, and Ab42 was performed on the Luminex plat-
form (Luminex Corporation, Austin, TX) using the multi-
plexed AlzBio3 (Fujirebio, Ghent, Belgium) kit as
instructed in kit inserts. For biomarker correlation analysis,
ALS patients were merged, due to the low number of pa-
tients per group. Patients with variants of primary progres-
sive aphasia were similarly merged for correlation analysis.
2.4. Brain homogenization, western blotting, and
immunoprecipitation
Brain samples were taken from the superior parietal gyrus
of AD subjects. Homogenization of brain tissue, western blot-
ting, and immunoprecipitation of CSF was performed as pre-
viously described [28], with minor modifications (see
Supplementary Material for a detailed description). Full-
length recombinant GAP-43 protein was produced in house
(see Supplementary Material) and compared to endogenous
GAP-43 protein by western blotting in the brain and CSF.
2.5. In-house GAP-43 sandwich ELISA
The ELISAwas developed in house combining the mouse
monoclonal GAP-43 antibody NM4 (Fujirebio) and a poly-
clonal GAP-43 antibody (ABB-135, Nordic Biosite, T€aby,
Sweden) with a C-terminal epitope. For detailed description,
see Supplementary Material. The analyses were performed
by board-certified laboratory technicians blinded to clinicalFLA 5.5.0 DTD  JALZ2745_proof information. During sample runs in the clinical evaluation
study, the repeatability CV% of control samples, with the
concentrations 3157 pg/mL and 857 pg/mL, was 5.5%
versus 11% and the interassay CV% was 6.9% versus
15.6% across 18 ELISA plates.2.6. In-house GAP-43 ELISA validation
The performance of the novel ELISAwas evaluated using
leftover CSF samples from clinical routine of the Neuro-
chemistry laboratory, Sahlgrenska University Hospital,
M€olndal, Sweden (see Supplementary Material for an eval-
uation of precision, LLOQ, recovery, and sample dilution
linearity).2.7. Statistical analysis
Statistical analysis was performed using SPSS version
23.00 (IBM, NY, USA) and GraphPad Prism 7.0 (GraphPad
Inc., CA, USA). As the biomarker data were not normally
distributed, nonparametric statistics were used. Unless
otherwise stated, demographics and clinical characteristics
were summarized using medians and interquartile ranges
for biomarkers and analyzed by Mann-Whitney U-test,
Kruskal-Wallis test, and chi-square test. Comparisons of
biomarker concentrations were performed using Kruskal-
Wallis test and Spearman rank correlations. Statistical tests
were two sided with significance threshold value of
P , .05. The significance level was adjusted to P , .003
to compensate for multiple comparisons for associations of
CSF GAP-43 and pathology severity across 17 brain regions.3. Results
3.1. GAP-43 detection in brain and CSF by western
blotting
To ensure specificity of the antibodies used for quantifica-
tion of GAP-43 by ELISA, brain and CSF samples were pro-
cessed for western blotting and GAP-43 was detected as a
single band around 43 kDa in soluble and insoluble protein
fractions of brain extracts by the antibodies NM4 and
ABB-135 (Supplementary Fig. 1A). After immunoprecipita-
tion of CSF with the same antibodies, a band corresponding
to GAP-43 was detected aligning with that of recombinant
GAP-43 (Supplementary Fig. 1B).3.2. In-house ELISA characterization
Results from assay characterization are summarized in
Supplementary Table 2. CSF GAP-43 quantification with
NM4-ABB135 immunoassay was stable after one to four
freeze thaw cycles (n 5 9; 100.9%–107.9%), and various
storage temperatures (n 5 7; 94.8%–103.5%, percentage
of 280C stored aliquot concentration).2 November 2018  10:29 pm  ce
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The novel GAP-43 ELISA was tested in a pilot study
including 12 AD patients and 15 control subjects. Control
subjects were significantly younger than AD subjects; how-
ever, no correlation of GAP-43 with age was detected. CSF
GAP-43 concentration was twofold higher in the AD pa-
tients compared to controls (P 5 .001, Supplementary
Fig. 2). Based on these results, a clinical follow-up study
was performed to validate the findings.
3.4. Demographics of clinical validation study
Demographics of participants in the validation study are
provided in Table 1. The clinical AD group was age and
gender matched to controls and MCI patients. Age corre-
lated weakly with CSF GAP-43 across the study population
(rs 5 0.11, P 5 .004), but not in separate clinical diagnostic
groups. Across all diagnostic groups, GAP-43 concentra-
tions were higher in females than in males (median female:
2880 pg/mL, median male: 2547 pg/mL, P 5 .001) and re-
mained significant only in the AD group after division by
clinical diagnosis (median AD female: 3489 pg/mL, median
ADmale: 3023 pg/mL, P5 .017). No statistically significant
differences in GAP-43 concentrations were detected based
on ethnicity, education years, handedness, or MAPT H1/
H2 haplotypes.
3.5. CSF GAP-43 concentration in AD and MCI patients
CSFGAP-43 concentrationswere significantly increased in
clinical AD patients compared to controls (P, .0001), but not
in clinical MCI patients (Fig. 1A). Of all the patients includedTable 1
Demographics of participants in the clinical evaluation study





Control 43 69 (9.1) 69.8 70.7 26.8 2.3 2
MCI 84 72 (8.9) 46.4* 51.2 27.4 3.6 2
AD 275 71.2 (9.2) 58.2 34.2 38.5 13.1 2
ALS 53 58 (11.5)*,yyy 26.4***,yyy 73.6 20.8 1.9 2
FTD 39 61 (7.7)*,yyy 30.8**,yy 66.7 25.6 2.6 2
PD 28 65.9 (7.2) 32.1**,y 85.7 10.7 / 2
PD-MCI 14 63.4 (5.7) 14.3**,y 61.5 38.5 / 2
PD-demented 15 74.3 (6.9) 20*,y 66.7 33.3 / 2
DLB 27 73 (9.2) 44.4 44.4 29.6 7.4 1
PPA (logopenic) 10 62.6 (6.1) 60 33.3 66.7 / 2
PPA (PNFA) 16 63.7 (9.4) 43.3 43.8 43.8 12.5 2
PPA (SD) 15 62.5 (8.1) 66.7 80 13.3 6.7 2
PSP 18 70.2 (9.2) 55.6 88.9 11.1 0 2
CBS 19 66.2 (7.2) 57.9 73.7 21.1 5.3 2
PCA 6 60 (6.2) 83.3 50 33.3 0 2
Abbreviations: SD, standard deviation; F, female; MMSE, Mini–Mental State
impairment; AD, Alzheimer’s disease; ALS, amyotrophic lateral sclerosis; FTD
Lewy bodies; PPA, primary progressive aphasia; PSP, progressive supranuclear p
NOTE. Biomarker concentrations are median and interquartile range.
NOTE. *Indicates differences compared to control group; *P , .05. yIndicates
yyyP , .0001.
FLA 5.5.0 DTD  JALZ2745_proof in the study, 56 had a definitive Alzheimer’s neuropathological
diagnosis, and therewas a trend toward increasedCSFGAP-43
concentrations in this group compared to clinical AD. To iden-
tify possible clinical misdiagnosed patients, a neurochemical
cutoff based on the INNO-BIA AlzBio3 T-tau/Ab42 ratio
(AD positive: ratio .0.48, T-tau: 93 pg/mL and Ab42: 192
pg/mL) suggestedbyShawet al. [29]wasapplied to the clinical
AD group. The ratio identified 209 biomarker-defined AD
biomarker-positive patients out of the 275 clinically diagnosed
patients and CSF GAP-43 concentrations were significantly
higher in AD biomarker-positive compared to biomarker-
negative clinicalADpatients (P,.001, Fig. 1B). Furthermore,
patients without a positive T-tau/Ab42 ratio displayed GAP-43
concentrations equal to controls (Fig. 1B). MCI patients were
similarly divided by the T-tau/Ab42 cutoff, and the
biomarker-positive MCI group had significantly increased
CSF GAP-43 concentrations compared to the biomarker-
positive MCI group (P, .0001, Fig. 1C).3.6. CSF GAP-43 concentration in AD differential
diagnoses
Apart from AD patients, only lvPPA patients had altered
CSF GAP-43 concentration compared to controls (P 5 .01,
Fig. 1F). The CSF GAP-43 concentrations in AD patients
were compared in three subgroups of differential diagnoses:
(1) Parkinsonian disorders and Parkinson’s disease; (2) ALS;
and (3) atypical AD and subgroups of FTD diagnoses.
CSF GAP-43 concentrations in clinical AD patients were
significantly increased compared to both Parkinson’s disease
and Parkinsonian disorders (nondemented P 5 .0002,
demented P 5 .027, with MCI; P 5 .0002), DLBMSE score





8.9 (2.4) 23346(1104) 526(25) 2506(111) 176(10)
6.1 (3.5) 23726(1972) 586(54) 1766(104) 166(25)
1.2 (5.8) 32026(1800) 1066(81) 1356(57) 376(29)
6.8 (4) 20786(1228) 496(33) 2726(104) 116(6)
5.4 (3.6) 23196(1274) 626(38) 2436(145) 146(10)
8.7 (1.6) 23496(1033) 456(21) 2836(64) 186(15)
8.4 (1.3) 20226(812) 396(19) 2146(71) 186(20)
5.6 (4.6) 25506(1038) 476(32) 2626(72) 226(14)
9.4 (6.6) 21956(2303) 516(50) 4146(38) 156(22)
2.5 (5.7) 33506(2346) 1396(64) 1316(31) 396(16)
2.5 (4.9) 23506(1851) 596(45) 2246(110) 176(17)
2.9 (5.3) 30406(2212) 946(62) 2896(101) 156(13)
6.4 (4.3) 17726(1811) 506(39) 2106(144) 126(8)
4.5 (4) 32006(2103) 766(45) 2256(109) 216(13)
2.8 (5.5) 22646(1859) 536(82) 2066(184) 266(26)
Examination; GAP-43, growth-associated protein 43; MCI, mild cognitive
, frontotemporal dementia; PD, Parkinson’s disease; DLB, dementia with
alsy; CBS, corticobasal syndrome; PCA, posterior cortical atrophy.
differences compared to Alzheimer’s disease group; yP , .05, yyP , .001,
2 November 2018  10:29 pm  ce
Fig. 1. Clinical evaluation of CSF GAP-43 quantification in control, MCI and Alzheimer’s disease and differential diagnoses to Alzheimer’s disease. (A) CSF
GAP-43 concentration was increased in patients with a clinical AD diagnosis, whereas clinical MCI patients were similar to control level. The median CSF
GAP-43 concentration was particularly increased in a group of AD patients with a neuropathologically confirmed AD diagnosis (NPD-AD). (B) Applying a
neurochemical cut off (IB AlzBio3 T-Tau/IB AlzBio3 Ab42 ratio [.0.485 AD]), identified a large proportion of clinical AD patients with lower GAP-43 con-
centrations which were biomarker negative. (C) MCI patients with a T-tau/Ab42 ratio above the cut off had increased GAP-43 concentration whereas MCI pa-
tients below the cut off were similar to control. (D) CSFGAP-43 concentration was increased in clinical AD patients compared to PD patients without dementia,
withMCI or demented, DLB patients and PSP, whereas patients with CBS displayed comparable levels. (E) CSFGAP-43 concentration was increased in clinical
AD patients compared to ALS, whereas therewas no significant difference to ALSwithMCI or ALSwith FTD. (F) CSFGAP-43 concentration was increased in
clinical AD patients compared to bvFTD and naPPA, whereas lvPPA and svPPA variants and PCA patients displayed comparable levels. The solid and dotted
lines indicate the median and IQR of the neurochemical control group. Concentrations are medians with interquartile range. *P, .05; ***P, .001; ****P,
.0001. Abbreviations: AD, Alzheimer’s disease; ns, not significant; NPD-AD, neuropathologically confirmed Alzheimer’s disease; MCI, mild cognitive impair-
ment; AD1, clinical Alzheimer’s disease patients with a positive T-Tau/Ab42 ratio; AD -, clinical Alzheimer’s disease patients with a negative T-Tau/Ab42 ratio;
MCI 1, clinical MCI patients with a positive T-Tau/Ab42 ratio; MCI -, clinical MCI patients with a negative T-Tau/Ab42 ratio; PD, Parkinson disease; PSP,
progressive supranuclear palsy; CBS, corticobasal syndrome; ALS, amyotrophic lateral sclerosis; bvFTD, behavioural variant frontotemporal lobar degener-
ation; lvPPA, logopenic variant of primary progressive aphasia; svPPA, semantic dementia variant of primary progressive aphasia; naPPA, progressive nonfluent
aphasia variant of primary progressive aphasia; PCA, primary cortical atrophy.
A. Sandelius et al. / Alzheimer’s & Dementia- (2018) 1-10 5(P5 .018), and progressive supranuclear palsy (P5 .0004),
while there were no differences in the concentrations be-
tween AD and corticobasal syndrome patients (P . .99,
Fig. 1D). Eighteen percent of corticobasal syndrome patients
had a T-tau/Ab42 ratio indicative of AD.
ALS (P, .0001) and bvFTD (P, .0001) both had signif-
icantly lower GAP-43 concentrations compared to AD
(Fig. 1E and F). The ALS patients with additional MCI or
additional FTD were not significantly different from AD pa-
tients (P . .999 and P 5 .138, respectively, Fig. 1E).FLA 5.5.0 DTD  JALZ2745_proof The FTD spectrum includes several related disorders in
which progressive degeneration of the frontal and temporal
lobes is common [30,31]. On the basis of clinical
phenotypes, we compared AD to FTD subgroups and
atypical AD; PCA, bvFTD, and PPA of which the later
was further divided into naPPA, lvPPA, and svPPA [30].
naPPA had significantly lower GAP-43 concentrations
(P 5 .022, Fig. 1F), whereas PCA (P 5 .182), lvPPA, and
svPPA patients had similar CSF GAP-43 concentrations as
AD patients (both P . .99, Fig. 1F). Seventy percent of2 November 2018  10:29 pm  ce
Table 2
Spearman’s correlation analysis of GAP-43 concentration with CSF biomarkers of Alzheimer’s disease pathology
Diagnostic group
IB AlzBio3 T-tau (pg/mL) IB AlzBio3 Ab42 (pg/mL) IB AlzBio3 PTau (pg/mL)
rs P n rs P n rs P n
Control 0.841 ,.0001 42 20.083 .595 43 0.356 .019 43
All MCI 0.908 ,.0001 83 20.066 .551 83 0.649 ,.0001 83
AD 0.818 ,.0001 261 20.131 .034 262 0.516 ,.0001 262
ALS 0.806 ,.0001 52 0.531 ,.0001 53 0.456 .001 52
FTD 0.752 ,.0001 32 0.149 .408 33 0.384 .03 32
PD not demented 0.639 ,.0001 26 0.346 .083 26 0.055 .791 26
PD-MCI 0.7 .005 14 20.407 .149 14 0.569 .034 14
PD with dementia 0.688 .007 14 0.368 .177 15 0.45 .092 15
DLB 0.892 ,.0001 18 20.077 .753 19 0.522 .022 19
PPA 0.782 ,.0001 31 0.092 .621 31 0.207 .265 31
PSP 0.829 ,.0001 17 0.437 .08 17 0.692 .002 17
Corticobasal syndrome 0.676 .011 13 0.407 .168 13 20.58 .851 13
Abbreviations: MCI, mild cognitive impairment; AD, Alzheimer’s disease; ALS, amyotrophic lateral sclerosis; FTD, frontotemporal dementia; PD, Parkin-
son’s disease; DLB, dementia with Lewy bodies; PPA, primary progressive aphasia; PSP, progressive supranuclear palsy.
A. Sandelius et al. / Alzheimer’s & Dementia- (2018) 1-106patients with lvPPA and 13% of patients with svPPA had T-
tau/Ab42 ratios indicative of AD.3.7. CSF GAP-43 concentration correlates with core AD
biomarkers
Biomarker correlations were performed in patient groups
with at least 10 patients and are presented in detail in Table 2.
Strong correlations were found between GAP-43 and T-tau
in all clinical groups. Furthermore, GAP-43 correlated
moderately with P-tau inMCI patients, AD, ALS, DLB, pro-
gressive supranuclear palsy, PD with MCI, and weakly in
FTD patients and controls. A weak negative correlation
was found between GAP-43 concentration and Ab42 in clin-
ical AD and surprisingly a moderate positive correlation
with Ab42 in ALS patients (Table 2).3.8. CSF GAP-43 concentration correlates with cognitive
decline and AD pathology
CSF GAP-43 concentrations correlated weakly with
MMSE scores when including all diagnostic groups
(rs520.21, P, .0001, n5 593, Fig. 2A), but no significantFig. 2. CSF GAP-43 concentration is associated with cognitive decline. (A)
Lower MMSE scores was correlated to higher CSF GAP-43 concentration
across all diagnostic groups. (B) MMSE change per year across all diagnostic
groups indicates increasing concentration of CSF GAP-43 with larger decline
in MMSE. Abbreviation: MMSE, Mini–Mental State Examination.
FLA 5.5.0 DTD  JALZ2745_proof correlations were detected in clinical subgroups. In addition,
the longitudinal decrease in MMSE score per year correlated
weakly with increasing GAP-43 concentration (rs5 20.26,
P5 .0001, n5 305, Fig. 2B). Similar toMMSE scores, there
were no correlations of GAP-43withMMSE change per year
when dividing the cohort by clinical diagnosis. CSF GAP-43
correlated with Braak neurofibrillary tau staging (rs 5 0.41,
P 5 .0001) and was significantly higher in stage V–VI
compared to 0 Braak scores (P 5 .001, n 5 91, Fig. 3A).
Furthermore, GAP-43 correlated with CERAD score of Ab
deposition across all diagnostic groups (rs 5 0.37,
P,.0001) andwas significantly higher for scoreC compared
to 0 (P5 .001, n5 92, Fig. 3B). GAP-43 concentration was
negatively correlated to brain weight (rs520.30, P5 .003,
n 5 94) but not associated to hippocampal sclerosis.
Examination and scoring of tau, thioflavin/amyloid, a-
synuclein and TDP-43 pathology, amyloid angiopathy, glio-
sis, and neuron loss carried out in 17 brain regions revealed
that CSF GAP-43 concentration was specifically associated
with AD pathology. GAP-43 concentration increased signif-
icantly with severity scores of amyloid pathology in the CA/
subiculum hippocampus region and amygdala (Fig. 3C and
D), and severity of both tau and amyloid pathology in the
angular gyrus, superior-midtemporal cortex, and anterior
cingulate cortex (Fig. 3E–H, J and K). In the occipital cortex,
GAP-43 was increased with tau pathology (Fig. 3I). In the
midfrontal cortex, GAP-43 increasedwith only tau pathology
and gliosis (Fig. 3L andM).No differencewas found inGAP-
43 concentration across the severity grades of a-synuclein,
amyloid angiopathy, and TDP-43 pathology in any brain
region.3.9. CSF GAP-43 concentration in APOE ε4 carriers
GAP-43 concentration was higher in subjects with one or
two APOE ε4 alleles compared to subjects with no APOE ε4
alleles (0 vs. 1; P, .0001, vs. 2; P, .0001, Fig. 4A). There
was also a statistically significant decrease in GAP-432 November 2018  10:29 pm  ce
Fig. 3. CSF GAP-43 concentration is associated with disease severity. (A) CSF GAP-43 concentration was increased in patients with high Braak scores (0 to V-
VI; P5 .0027). (B) CSF GAP-43 concentration was increased in patients with high CERAD scores (0 to C; P5 .0012). (C-M) GAP-43 concentration increased
with amyloid plaque and/or Tau pathology (05 none, 0.55 rare, 15mild, 25moderate, 35 severe) in CA/subiculum hippocampus region (CS), amygdala
(Amyg), angular gyrus (Ang), superior-middle temporal cortex (SMT) occipital cortex (OC), anterior cingulate cortex (Cing), mid-frontal cortex (MF), and
gliosis in mid-frontal cortex. Scores 0 and 0.5 were merged due to low numbers in the 0.5 core group. **P , .003; ***P , .001.
A. Sandelius et al. / Alzheimer’s & Dementia- (2018) 1-10 7concentration in subjects with one or two APOE ε3 alleles
compared to subjects with no APOE ε3 allele (0 vs. 2;
P 5 .0001, 1 vs. 2; P , .0001, Fig. 4B). When stratifiedFLA 5.5.0 DTD  JALZ2745_proof based on clinical diagnosis, GAP-43 was only increasing
with the number of APOE ε4 alleles in AD patients
(n 5 236, P 5 .022, n (0) 5 94, n (1) 5 106, n (2) 5 36;2 November 2018  10:29 pm  ce
Fig. 4. GAP-43 concentration increased with the number of APOE 34 al-
leles. (A) GAP-43 concentration increased with the number of APOE 34 al-
leles across all diagnostic groups. (B) GAP-43 concentration decreased with
the number of APOE 33 alleles across all diagnostic groups. (C) GAP-43
concentration increased with the number of APOE 34 alleles in AD patients
and (D) MCI patients. *P , .05; ****P , .0001. Abbreviations: AD, Alz-
heimer’s disease; MCI, mild cognitive impairment.
A. Sandelius et al. / Alzheimer’s & Dementia- (2018) 1-108pairwise comparison: 0 vs. 1; P 5 .028, vs. 2; P 5 .046,
Fig. 4C) and MCI patients (P 5 .038, n (0) 5 43 n
(1) 5 23, n (2) 5 3, pairwise comparison 0 vs. 1; P 5 .03,
vs. 2; P5 .242, Fig. 4D), but not in the other neurodegener-
ative diseases or controls.4. Discussion
In this study, we quantified CSF GAP-43 in patients with
different neurodegenerative dementias, including for the first
time a large number of neuropathologically confirmed AD
patients and important differential diagnoses such as several
frontotemporal dementia diagnoses and PD and Parkinso-
nian disorders. Our results are in line with previous findings
reporting increased CSF GAP-43 levels in AD [23,24], and
patients with MCI due to AD [23]. However, the GAP-43 in-
crease was more pronounced in our study compared to two
previous studies [24,25], which may be due to assay
differences or mixed patient cohorts at the time. We
showed that GAP-43 can be reliably quantified in CSF by
a novel in-house sandwich ELISA. Importantly, using this
cohort, we show that CSF GAP-43 is associated with AD pa-
thology, specifically increased in patients with high Braak
neurofibrillary tangle stages and CERAD scores and in pa-
tients with moderate to severe tau and Ab neuropathology,FLA 5.5.0 DTD  JALZ2745_proof particularly in the hippocampus, amygdala, temporal and
occipital lobe. As there was only one association to gliosis
and no associations to the extent of TDP-43, a-synuclein,
or amyloid angiopathy, we conclude that these pathologies
have no major influence on GAP-43 CSF concentration.
These findings suggest that CSF GAP-43 could be an AD-
specific biomarker as the concentrations follow amyloid
and tau deposition in the brain and is not increased to the
same extremes in any other neurological disease tested
here. The positive correlation of GAP-43 with biomarker
levels of T-tau and P-tau and the negative correlation with
Ab42 are in line with the findings of increased GAP-43 con-
centration with increased severity of tau and amyloid depo-
sition in the brain. This indicates that there is a specific
association between synaptic, tau, and amyloid pathology
in AD; however, the biological connection between the three
is yet to be demonstrated. Furthermore, low MMSE score
and decline in MMSE score over time were weakly associ-
ated to higher GAP-43 concentration when analyzed in all
the groups. The lack of association in subgroups may be
due to several converging factors. GAP-43 concentrations
could be saturated in AD patients resulting in a lack of cor-
relation to MMSE change over time. As GAP-43 is a regu-
lator of synaptic plasticity and regenerative axonal growth
and induced by both injury and cognitive stimulation
[18,19,32], there is also a possibility that GAP-43 increases
with improvement in MMSE. Further studies are necessary
to clarify this. GAP-43 was specifically increased in AD
when compared to most other dementia disorders analyzed,
and therefore, it could become useful for differential diag-
nosis. CSF GAP-43 concentrations in patients with cortico-
basal syndrome, PCA, lvPPA and svPPA were not
significantly different from AD patients, which is expected
as these clinical syndromes often have underlying AD pa-
thology [1,33–35]. Several of these patients had a
neurochemical T-tau/Ab42 ratio indicative of AD
pathology which may partly explain the elevated CSF
GAP-43 concentrations. For comparison, a study by Lee
et al. reported presence of AD pathology in 32% of clinical
corticobasal syndrome patients, whereas 17% of these pa-
tients in our study had a positive AD biomarker profile
[35]. A substantial proportion of patients with variants of pri-
mary progressive aphasia are known to display AD pathol-
ogy [36,37], and CSF biomarker profile, based on Ab42/
Ab40, PIB PET, T-tau, and P-tau analysis [38–40]. The low
number of patients in the PCA group makes it
inappropriate to draw definite conclusions regarding this
group.
It has been reported that evaluations of novel biomarkers
may underestimate their potential due to a proportion of clin-
ically misdiagnosed patients. Several studies suggest an
increased accuracy of the diagnosis, based on simultaneous
neuropathological assessment or when using neurochemical
cutoffs based on tau and Ab42 quantification [1,29]. We
applied a neurochemical T-tau/Ab42 ratio cutoff described
in the study by Shaw et al., to reclassify the clinical AD2 November 2018  10:29 pm  ce
A. Sandelius et al. / Alzheimer’s & Dementia- (2018) 1-10 9patients. The biomarker-positive AD group had GAP-43
concentrations similar to the neuropathologically confirmed
AD group indicating a valid classification. The neurochem-
ical division of the MCI patients indicates that GAP-43 may
be useful to predict conversion from MCI to AD; future lon-
gitudinal studies should address this further.
Unexpectedly, there was a strong positive correlation of
GAP-43 concentration with Ab42 selectively in ALS pa-
tients. Peripheral levels of amyloid precursor protein and
Ab species have been reported to increase with disease onset
in both ALS mouse models and patients and suggested to be
directly involved in nerve degeneration [41–43]. This
finding could also reflect that this is the only disease group
included which does not have significant Ab pathology
(only 7.5% biomarker-positive ALS patients) and CSF con-
centrations of Ab42 and GAP-43 are the result of secretion in
normally functioning synapses. Possibly, the GAP-43 con-
centration reflects a concurrent increase with Ab42 concen-
tration in ALS patients due to neurodegeneration;
however, neither biomarker reaches the level of AD patients.
Furthermore, GAP-43 was especially high in AD and
MCI patients who were also APOE ε4 carriers, suggesting
that this phenotype is connected to an early synaptic vulner-
ability leading to the early cognitive decline.
In conclusion, CSF concentration of the presynaptic pro-
tein GAP-43 is specifically increased in tau- and amyloid-
positive individuals and could therefore be used as a marker
of synaptic dysfunction in AD, provide an additional
outcome measure in clinical trials, and help to separate pa-
tients with AD from patients with other forms of neurode-
generative diseases.Acknowledgments
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1. Systematic review: We reviewed studies investi-
gating the presynaptic protein growth-associated
protein 43 (GAP-43) in cerebrospinal fluid (CSF)
as a biomarker for Alzheimer’s disease, identifying
five research articles using the search terms “GAP-
43,” “cerebrospinal fluid,” and “Alzheimer’s” in the
PubMed database. One exploratory study indicated
that CSF GAP-43 may be increased in preclinical
Alzheimer’s disease and another suggested a
decrease in Parkinson’s disease although no larger
biomarker study was conducted.
2. Interpretation: Our findings suggest that CSF GAP-
43 concentration is specifically associated to Alz-
heimer’s disease pathology and correlated with
cognitive decline, whereas no connection was found
to the extent of a-synuclein and TDP-43 pathology.
3. Future directions: CSF GAP-43 may be useful as a
synaptic outcome marker in clinical trials of Alz-
heimer’s disease drugs and could facilitate early and
differential diagnosis. The results need to be repli-
cated in other cohorts, and longitudinal studies
would be highly interesting to determine how early
GAP-43 is affected.References
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